Inozyme Pharma Inc (INZY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inozyme Pharma Inc (INZY) has a cash flow conversion efficiency ratio of -0.917x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.15 Million) by net assets ($31.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INZY company net worth for the company's overall valuation and market capitalisation.
Inozyme Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Inozyme Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inozyme Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inozyme Pharma Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Inozyme Pharma Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ginwa Enterprise Group Inc
SHG:600080
|
0.019x |
|
Genesyslogic
TWO:6104
|
0.039x |
|
Cipher Pharmaceuticals Inc
TO:CPH
|
0.022x |
|
Perimeter Acquisition Corp. I Class A Ordinary Shares
NASDAQ:PMTR
|
0.000x |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
0.181x |
|
Enel Generacion Costanera SA
BA:CECO2
|
0.025x |
|
Namchow Chemical Industrial Co Ltd
TW:1702
|
0.030x |
|
BRT Realty Trust
NYSE:BRT
|
0.012x |
Annual Cash Flow Conversion Efficiency for Inozyme Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Inozyme Pharma Inc from 2018 to 2024. View Inozyme Pharma Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.83 Million | $-91.91 Million | -1.589x | -215.92% |
| 2023-12-31 | $140.48 Million | $-70.67 Million | -0.503x | -3.12% |
| 2022-12-31 | $118.39 Million | $-57.76 Million | -0.488x | -10.71% |
| 2021-12-31 | $109.27 Million | $-48.15 Million | -0.441x | -93.68% |
| 2020-12-31 | $158.10 Million | $-35.97 Million | -0.228x | -140.18% |
| 2019-12-31 | $-33.22 Million | $-18.81 Million | 0.566x | -16.75% |
| 2018-12-31 | $-13.88 Million | $-9.44 Million | 0.680x | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more